+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments



Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments



Diabetes and Metabolism 30(6): 549-556



Diabetic foot ulcers (DFU), infections and amputations are associated with high costs of care and loss of health. To evaluate new treatments, both the extra costs incurred and the health utility gained need to be examined. However, evaluations of treatments in diabetes are hampered by the lack of utility values for health states such as DFU. We estimated utility values for health states seen amongst DFU patients. We identified 13 unique health states based on presence/type of DFU and amputation. Members of the general public (n=107) received a description of each health state. They were then asked to indicate how undesirable each health state was (using the time trade-off method). Each answer was then transformed to create a value representing the "utility" of the health state, the utility value represented on a 0-1 scale. Valid responses could be obtained from 96 persons. Mean values included: 0.84 (diabetes with no DFU or amputation), 0.75 (uninfected DFU, no amputation), 0.68 (no DFU, previous foot amputation), and 0.63 (uninfected DFU, previous amputation of other foot). The impact of an ulcer depended on amputation status. Our values correspond with previously published results but are more detailed. In addition, since our values were derived from the general public, economic evaluations that incorporate them will use the generally preferred societal perspective. Therefore, these values are appropriate, practical and sensitive weights to calculate QALYs for cost-effectiveness analyses of foot ulcer treatments.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048768851

Download citation: RISBibTeXText

PMID: 15671925


Related references

The cost of diabetic foot ulcers and amputations to the National Health Service in England. Diabetic Medicine 36(8): 995, 2019

Cost-Effectiveness and Cost-Utility of Intralesional Recombinant Human Epidermal Growth Factor for Adjuvant Treatment of Wagners 3 and 4 Diabetic Foot Ulcers. Value in Health 19(7): A673-A674, 2016

Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia 44(11): 2077-2087, 2001

The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 21(16): 1171-1183, 2003

Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses. Spine 39(22 Suppl 1): S9, 2014

Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy/Wound Management 49(11): 76-84, 2003

Cost-effectiveness of becaplermin gel on wound healing of diabetic foot ulcers. Wound Repair and Regeneration 23(3): 353-360, 2016

The cost-effectiveness of graftskin vs standard care for diabetic foot ulcers. Diabetes 50(Suppl. 2): A496, 2001

Cost-effectiveness of Dermagraft for the treatment of diabetic foot ulcers in France. Diabetologia 42(Suppl. 1): A308, 1999

Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. Diabetes Research and Clinical Practice 70(1): 31-37, 2005

The Reduction of Diabetic Foot Amputations Starts with Preventing Foot Ulcers. Advances in Skin and Wound Care 31(9): 389, 2018

Diabetic foot and lower limb amputations: underestimated problem with a cost to health system and to the patient. Anz Journal of Surgery 88(7-8): 666-667, 2018

A cost-effectiveness analysis of optimal care for diabetic foot ulcers in Australia. International Wound Journal 14(4): 616-628, 2017

Economics of a new treatment for diabetic foot ulcers The cost-effectiveness of Becaplermin in Sweden. Diabetologia 42(Suppl. 1): A309, 1999

Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatologic Surgery 27(4): 347-351, 2001